andromeda: daratumumab for al amyloidosis
Published 4 years ago • 665 plays • Length 4:30Download video MP4
Download video MP3
Similar videos
-
2:36
andromeda: daratumumab cybord for al amyloidosis
-
3:56
andromeda: daratumumab plus vcd in al amyloidosis
-
1:50
andromeda: daratumumab & cybord for newly diagnosed al amyloidosis
-
5:07
daratumumab in the management of al amyloidosis
-
2:43
impact of the addition of daratumumab to the frontline treatment of patients with al amyloidosis
-
2:41
optimizing the use of daratumumab in al amyloidosis
-
3:23
novel agents and clinical trials emerging for the treatment of al amyloidosis
-
2:00
andromeda trial: d-vcd versus vcd in the treatment of patients with newly diagnosed al amyloidosis
-
1:45:40
what's new and exciting in attr cardiac amyloidosis in 2024
-
6:47
al amyloidosis and a critical, early diagnosis
-
26:59
updates on al amyloidosis treatment: what’s new in 2024
-
0:53
redefining the standard of care in al amyloidosis
-
0:44
outcomes of patients with al amyloidosis after failure of daratumumab-based therapy
-
2:46
single use daratumumab for al amyloidosis
-
3:07
daratumumab-based frontline therapy in al amyloidosis: real-world mayo clinic experience
-
1:53
altitude: venetoclax, daratumumab, and dexamethasone in systemic al amyloidosis with t(11;14)
-
0:54
the potential of daratumumab alone or with cybord in patients with stage iv al amyloidosis
-
1:48
a phase ii study of daratumumab and pomalidomide in previously treated patients with al amyloidosis
-
2:42
final results of the dart4mm study of daratumumab for mrd eradication in myeloma
-
1:21
andromeda study: updated safety run-in results
-
2:54
main results from the andromeda study
-
1:41
defining the optimal duration of treatment with daracybord & dara maintenance in al amyloidosis